Cancer Drugs Have The Worst Phase III Track Record, BIO Study Shows
This article was originally published in The Pink Sheet Daily
New data indicating that only one-third of oncologic agents succeed in Phase III, coupled with tougher regulatory hurdles ahead, could give big pharma and investors pause before committing resources in the therapeutic category.
You may also be interested in...
Crop of new treatments with data at the European Society of Medical Oncology meeting includes second-generation inhibitors of ALK and heat shock protein 90.
Progression-free survival benefit fails to translate into overall survival in Phase III NSCLC study of c-Met inhibitor tivantinib, partnered with Daiichi Sankyo. ArQule shifts focus to an imminent, targeted second-line Phase III study of high-Met expressing hepatocellular cancer.
After a progression-free survival benefit failed to translate into overall survival in a Phase III NSCLC study of ArQule/Daiichi Sankyo’s c-Met inhibitor tivantinib, ArQule is shifting focus to an imminent, targeted second-line Phase III study in high-Met expressing hepatocellular cancer.